Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 42Endocrine 42Gastrointestinal 4CNS 4Thoracic 3Sarcoma 3Gynecologic 3NET 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 1086Neoplasms, Plasma Cell 255Lymphoma 157Lymphoma, Non-Hodgkin 150Hodgkin Disease 135Recurrence 130Leukemia, Lymphocytic, Chronic, B-Cell 130Precursor Cell Lymphoblastic Leukemia-Lymphoma 116Myelodysplastic Syndromes 111Leukemia 109Leukemia, Myeloid, Acute 106Lymphoma, Follicular 84Lymphoma, Mantle-Cell 83Lymphoma, B-Cell, Marginal Zone 82Burkitt Lymphoma 76Lymphoma, Large B-Cell, Diffuse 74Myeloproliferative Disorders 70Immunoglobulin Light-chain Amyloidosis 67Lymphoma, Large-Cell, Immunoblastic 65Hematologic Neoplasms 63Primary Myelofibrosis 58Leukemia, Myeloid, Chronic-Phase 57Leukemia, Myeloid, Accelerated Phase 51Leukemia, Myelogenous, Chronic, BCR-ABL Positive 49Waldenstrom Macroglobulinemia 46Blast Crisis 44Congenital Abnormalities 43Leukemia, Myelomonocytic, Chronic 42Dendritic Cell Sarcoma, Interdigitating 42Smoldering Multiple Myeloma 41

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Carcinoma, Anaplastic × Plasma cell × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡